MicroRNA-98 inhibits the cell proliferation of human hypertrophic scar fibroblasts via targeting Col1A1

Sheng Bi†, Linlin Chai†, Xi Yuan, Chuan Cao* and Shirong Li

Abstract

Background: Hypertrophic scarring (HS) is a severe disease, and results from unusual wound healing. Col1A1 could promote the hypertrophic scar formation, and the expression of Col1A1 in HS tissue was markedly higher than that in the normal. In present study, we aimed to identify miRNAs as post-transcriptional regulators of Col1A1 in HS.

Methods: MicroRNA-98 was selected as the key miRNA comprised in HS. The mRNA levels of miR-98 in HS tissues and the matched normal skin tissues were determined by qRT-PCR. MTT and flow cytometry were used to determine the influence of miR-98 on cell proliferation and apoptosis of HSFBs, respectively. Col1A1 was found to be the target gene of miR-98 using luciferase reporter assay. Luciferase assay was performed to determine the relative luciferase activity in mimic NC, miR-98 mimic, inhibitor NC and miR-98 inhibitor with Col1A13'-UTR wt or Col1A13'-UTR mt reporter plasmids. The protein expression of Col1A1 in HSFBs after transfection with mimic NC, miR-98 mimic, inhibitor NC and miR-98 inhibitor were determined by western blotting.

Results: The mRNA level of miR-98 in HS tissues was much higher than that in the control. Transfection of HSFBs with a miR-98 mimic reduced the cell viability of HSFBs and increased the apoptosis portion of HSFBs, while inhibition of miR-98 increased cell viability and decreased apoptosis portion of HSFBs. miR-98 inhibitor increased the relative luciferase activity significantly when cotransfected with the Col1A1-UTR reporter plasmid, while the mutant reporter plasmid abolished the miR-98 inhibitor-mediated increase in luciferase activity. Western blotting revealed that overexpression of miR-98 decreased the expression of Col1A1.

Conclusions: Overexpression of miR-98 repressed the proliferation of HSFBs by targeting Col1A1.

Keywords: miR-98, Col1A1, Apoptosis, Proliferation, HSFBs

Background

Hypertrophic scarring (HS) is a serious disease, and results from unusual wound healing. It has excessive deposition of extracellular matrix [1]. Hypertrophic scar fibroblasts (HSFBs) often show vicious characteristics, such as excessive deposition and proliferation [2]. Basic fibroblast growth factor (bFGF) is reported to promote mitosis and to have an effect on endothelial cells [3]. FGF-2 could regulate myocardial infarct repair and could influence cell proliferation, scar contraction, and ventricular function [4]. When damage occurs, scar tissue forms [5]. Study showed bFGF could alleviate the scar of the rabbit ear model in wound healing [6]. Collagen type I (Col1) is the main structural element of the extracellular matrix (ECM). It served as a critical role in the development and progression of HS and the expression of Col-1 level was increased in HS tissues [7, 8]. Guofang et al. reported the production of Col1 was inhibited by miR-181c knockdown or miR-10a overexpression in HF [9]. Xie et al. reported antisense oligodeoxynucleotide (ASODN) was effective in downregulating type I collagen gene expression and could prove to be useful in the treatment of scars [10]. Fibroblast collagen (Col) synthesis...
appears to be downregulated by keratinocyte-derived cytokines. Fibroblast growth factors and proinflammatory cytokines appear to be able partially to overcome this downregulation and to increase collagen synthesis [11].

miRNAs have putative roles in the regulation of myofibroblasts and thus playing a part in hypertrophic scarring of the skin. Previous study showed miRNAs could putatively regulate proteins with a known role in myofibroblast regulation and function, for example, collagen type I (Col1A1) [12]. MicroRNAs (miRNAs) are single-stranded RNA molecules and can influence cell proliferation and differentiation [13]. They can bind to the 3′-UTR of cognate mRNAs, which can lead to the degradation of mRNA [14]. Many studies showed they had roles in a lot of diseases, such as skin inflammatory disorders [15, 16]. Recently, some miRNAs have been reported to participate in HS. MicroRNA 98 is reported to be related with many cancers. It can suppress tumor angiogenesis by influencing the level of matrix metalloproteinase-11 [17]. Its expression has the potential predictive value in formalin-fixed paraffin-embedded tissue from patients with breast cancer, and can be used as a diagnostic mark [18]. In mice models, there is a negative correlation between miR-98 and IGF-1 [19]. MiR-98 has been demonstrated to mediate the antihypertrophic effect of thioredoxin (Trx1) [20].

In present study, we aimed to explore the effect of miR-98 on proliferation and apoptosis of HSFBs and the molecular mechanism.

**Methods**

**Tissue samples**

Twenty HS tissue samples and matched normal skin tissues were obtained from twenty different patients in Hospital of Shanghai Jiaotong from May 2011 to June 2015. The written informed consents had been signed by all patients in advance. The experiments were approved by ethics committee of Central South University (the ethics certificate number is CSUEC 2011-094). We separated samples into three groups: sample 1 was stored in 4% paraformaldehyde solution; sample 2 was stored in liquid nitrogen and sample 3 was stored to isolate and cultivate fibroblasts.

**Cell culture**

We obtained HSFBs and normal skin fibroblasts (NSFBs) (paired) from Ruijin Hospital, Affiliated to Shanghai Jiaotong University (Shanghai, China). We first cultivated fibroblasts in culture medium containing 0.5% fetal calf serum (FCS) after removing phenol red to train their adaptation in low serum concentration. Fibroblasts were cultivated in RPMI-1640 containing 10% inactivated FBS, penicillin (the concentration was 100 U/ml) and streptomycin (the concentration was 100 μg/ml) at 2D, 3D and Tis stage in a humidified cell incubator. The incubator contained 5% CO₂ and the temperature in it was 37 °C.

**Identification of differentially expressed miRNA**

Total RNAs were extracted from hypertrophic scar tissue and normal skin tissues using miRcute miRNA Isolation Kit (TIANGEN, China) according to the manufacturer’s instruction. The total 500 ng RNAs was subjected to an Agilent miRNA microarray analysis service (Bio Matrix Research, Nagareyama, Japan). Data analysis was done with the GenePix Pro software (LC Sciences). The miRNA array contained human probes. Probes with “present call” flag in at least one sample in both groups were used for further data analyses. Differences between groups were examined for statistical significance with unpaired Student t test. A P value <0.05 was considered statistically significant.

**Transfection of miR-98 mimic and inhibitor**

The 2′-O-me-miR-98 mimic and 2′-O-me-miR-98 inhibitor were obtained from GenePharma (Shanghai, China). The oligonucleotides were 2′-OMe modified. The transfection experiment was performed as previously described [21]. Briefly, cells were transfected with Lipofectamine 2000 (Invitrogen, CA, USA) and were analyzed 24 and 48 h after transfection.

**Quantitative real-time PCR analysis**

RNA was obtained from HS tissue samples and matched normal skin tissues by mirVana miRNA isolation kit ThermoFisher Scientific (Austin, TX). Trizol was put into the kit and shaked well. The solution was transferred into 1.5 ml tubes using chloroform and centrifuged at 12,000×g for 15 min. Supernate was put into EP tubes again with isopropanol and centrifuged, and the precipitate was kept. Precipitate was treated with ethanol and DEPC was used to dissolve the precipitate. NanoDrop 1000 spectrophotometer (NanoDrop Technologies, Wilmington, Delaware, USA) was used to determine RNA concentration. The expression level was normalized using U6 small nuclear RNA by the 2−ΔΔCt method. The ΔΔCt values were normalized to U6 level.

**Western blotting**

Fifty micrograms of total protein extracts from HS cells transfected with miR-98 mimics or miR-98 inhibitor was loaded on SDS-PAGE gels for Western blotting. Western blotting was performed by a standard protocol. The mouse monoclonal anti-human Col1A1 antibody (R&D Systems Europe Ltd.) was diluted 1:500. Quantification of
Western blot was performed by densitometry using the Storm 820 PhosphorImager.

Luciferase assay
According to target prediction software miRNA.org to predict the binding site of miR-98. The fragment was inserted into the 3′-end of the firefly luciferase gene of the dual-luciferasen miRNA target expression vector luciferase reporter vector (pGL3). The direct binding sites between miR-98 and Col1A1 3′ UTR were deleted by overlap extending PCR to construct pGL4.13-Col1A1-3′ UTR-mut.

Cell counting kit-8 assay
Cell proliferation assay was performed according to the instruction of CCK-8 kit (Solarbio, Beijing, China). Cells at logarithmic phase were made into single-cell suspension and seeded to 96 well plate with 5 × 10³ cells. At 1, 2, 3, 4 and 5 days after seeding, 10 μl of CCK-8 solution mixed with 90 μl of DMEM was added into each well. After 2 h incubation, absorbance was measured at 450 nm.

Flow cytometry
After transfection, cells were collected and made into single-cell suspension. The suspension was washed with PBS twice and fixed with 70% ethanol overnight. Propidium iodide (PI) single-stained reagent was added and placed avoiding light for 30 min. Flow cytometry (FCM) was used to determine the cell cycle in each group. The same method was used to collect cells, but fix was not performed with ethanol. AV/PI double-stained reagent was added and placed avoiding light for 10 min. FCM was used to determine apoptosis rate in each group. Each experiment was repeated for 3 times.

Statistical analysis
Statistical evaluation for data analysis was determined by unpaired Student’s t test. Data were presented as the mean ± SD and P values <0.05 were considered significant.

Results
Hsa-miR-98 was down-regulated in hypertrophic scar
To explore the key miRNAs consisted in HS, miRNAs data coming from human hypertrophic scars and mouse skin scar after wounding were downloaded from database and uploaded to GEO (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE26213; http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE30913) to screen differential expressed genes. Results showed 18 miRNAs were up-regulated by more than 1.5-fold, and 32 miRNAs were down-regulated by more than 1.5-fold (Fig. 1a). To further validate the miRNA microarray results, 5 out of the most obvious up-regulated miRNAs (miR-6723-5p, miR-1285-3p, miR-619-5p, miR-1290 and miR-1273a) and 5 out of the most obvious down-regulated miRNAs (miR-98, miR-7846-3p, miR-668-5p, miR-4738-3p and miR-4654) were selected to determine their relative expression levels on hypertrophic scar tissues to verify the effect of chips. Results showed that relative expression values of miR-6723-5p, miR-1285-3p, miR-619-5p, miR-1290 and miR-1273a were above 0 and that relative levels of miR-98, miR-7846-3p, miR-668-5p, miR-4738-3p and miR-4654 were below 0 (Fig. 1b). This indicated the results of miRNA microarray chips from human hypertrophic scars were precise. Moreover, from the results, we obtained the most differentially expressed up-regulated miRNA was miR-6723-5p and the most differentially expressed down-regulated miRNA was miR-98. Previous study showed the expression of miR-98 in keloid fibroblasts was low. Therefore, miR-98 was selected for further study. Twenty hypertrophic scar tissues and the matched normal skin tissues were prepared and the relative expression of miR-98 in them was determined by qRT-PCR. Results showed the relative expression of miR-98 in hypertrophic scar tissues was significantly lower than that in the matched normal skin tissues (Fig. 1c).

MiR-98 modulates hypertrophic scar fibroblast cell growth
We used qRT-PCR assay to determine the levels of miR-98 in NSFBs and HSBFs. The results were reported in Fig. 1c. As shown, hsa-miR-98 level of miR-98 in HSBFs was significantly lower than that in NSFBs (P < 0.001).

To explore the influence of miR-98 on HS, we transfected HSBFs with miR-98 mimic or inhibitor. After transfection for 24 h, we used qRT-PCR to determine the level of miR-98 in HSBFs. As shown in Fig. 2a, the level of miR-98 in miR-98 mimics group was significantly increased, while in miR-98 inhibitor group, the value decreased markedly (Fig. 2d). Then, we used MTT assay to determine cell viability. Results showed the cell viability of HSBFs reduced dramatically in miR-98 mimics (Fig. 2b), while cell viability in miR-98 inhibitor increased (Fig. 2e). FCM was used to determine the influence of miR-98 on cell apoptosis. Results showed apoptosis rate of HSBFs in miR-98 mimics group increased markedly compared with the control (Fig. 2c), while the apoptosis rate in miR-98 inhibitor decreased (Fig. 2f). All those indicated that miR-98 can influence the cell proliferation and apoptosis of HSBFs.

The Col1A1 gene is a direct target of miR-98 in HSBFs
Col1A1 was predicted to be the target gene of miR-98. In our study, results showed the wt of Col1A1 containing the potential miR-98 binding site (Fig. 3a). Luciferase
assay was performed to determine the relative luciferase activity in mimic NC, miR-98 mimic, inhibitor NC and miR-98 inhibitor with Col1A13'-UTR wt or Col1A13'-UTR mt reporter plasmids. Results showed the relative luciferase activity in miR-98 mimic group with Col1A13'-UTR wt reporter plasmid was markedly lower than the mimic NC group with Col1A13'-UTR wt, while the relative luciferase activity in miR-98 inhibitor group with Col1A13'-UTR wt reporter plasmid was markedly higher than the inhibitor NC group with Col1A13'-UTR wt, while the relative luciferase activity in miR-98 inhibitor group with Col1A13'-UTR wt reporter plasmid had no significant difference with the inhibitor NC group with Col1A13'-UTR wt. Moreover, the relative luciferase activity in miR-98 inhibitor group with Col1A13'-UTR wt reporter plasmid was markedly higher than the inhibitor NC group with Col1A13'-UTR wt, while the relative luciferase activity in miR-98 inhibitor group with Col1A13'-UTR wt reporter plasmid had no significant difference with the inhibitor NC group with Col1A13'-UTR wt. Then, the protein expression of Col1A1 in HSFBs after transfection with mimic NC, miR-98 mimic, inhibitor NC and miR-98 inhibitor were determined by western blotting. Results showed there was a significant reduction in Col1A1 expression after transfection with miR-98 mimic and a markedly increase after transfection with miR-98 inhibitor (Fig. 3c), which kept pace with the results of luciferase reporter assay.

MiR-98 was negative correlated with Col1A1
To further explore the regulatory roles of miR-98 in Col1A1 synthesis in vivo, we then determined the expression levels of miR-98 and Col1A1. An inversely relationship between miR-98 and Col1A1 was observed in skin scar ($R^2 = 0.6190$, $P < 0.001$) (Fig. 4).

Discussion
Hypertrophic scarring (HS) is a serious disease and can lead to grievous functional and esthetic defects [22]. The features of HSs include the proliferation of dermal tissue, of which there exists undue deposition of extracellular matrix proteins [23]. As reported, HS can result in substantial morbidity [24]. It plays a key role in preventing HS. Some research showed miRNAs play a key role in HS mechanism [25]. MiR-98 was reported to be an oncomir
in recurrent nasopharyngeal carcinoma, ovarian cancer and prostate cancer [26]. However, studies on reporting the expression and functions of miR-98 in HS were few. In this study, results indicated that miR-98 regulated the apoptosis, cell viability of HS cells by targeting Col1A1. These findings help us to explore the mechanism underlying HS formation and therapeutic strategies for this disorder.

Collagen is extracellular matrix (ECM) component and its disorganized accumulation can result in scar formation [27]. The change of collagen was reported to have a key role in HS. The deposition of I and III collagen can result in HS [28]. The expression of Col1A1 in HS tissue was markedly higher than that in the control [29]. Col1A1 could promote the hypertrophic scar formation [30]. Some studies showed when ECM proteins (such as pro-Col1A1) increased, the excessive scar fibrosis occurred [31]. Scars are characterized by excessive collagen deposition, particularly types I and III collagen [32].

In our study, results showed miR-98 can regulate Col1A1 expression by targeting the 3′-UTR of Col1A1. After HSFBs transfected with miR-98 mimic, the expression of Coll1A1 reduced, while the expression increased after transfection with miR-98 inhibitor. Moreover, after transfection with miR-98 mimic, the cell viability of HSFBs decreased and the apoptosis portion of HSFBs increased, while inhibition of miR-98 increased cell viability and decreased apoptosis portion of HSFBs. Fibroblast apoptosis had a key role in normal and pathological scar formation and the putative apoptosis-inducing factor curcumin affected fibroblast apoptosis and may function as a novel therapeutic [33]. It was known that 10-hydroxycamptothecin (HCPT) can prevent fibroblast proliferation, which further affect epidural scar adhesion after laminectomy in rats [34]. The presence or absence of scar was matched with the type of fibroblast generating the fetal wound matrix in a postnatal environment [35]. This suggested that HSFB proliferation was adjusted by decreased Col1A1 expression, which was resulted from the overexpression of miR-98. Those indicated that Col1A1 was a key downstream mediator of miR-98 in HSFBs.

**Fig. 2** a The relative expression of miR-98 in HSFBs after transfection with mimics NC and miR-98 mimics. b Cell viability of HSFBs was determined after transfection with mimics NC miR-98 mimics for 1, 2, 3, 4 and 5 days. c The apoptosis portion of HSFBs after transfection with mimics NC miR-98 mimics. *P < 0.05 and **P < 0.01, compared with mimic NC group, the relative expression, cell viability or apoptosis portion of HSFBs in miR-98 mimics had significant difference. d The relative expression of miR-98 in HSFBs after transfection with inhibitor NC and miR-98 inhibitor. e Cell viability of HSFBs was determined after transfection with inhibitor NC and miR-98 inhibitor for 1, 2, 3, 4 and 5 days. f The apoptosis portion of HSFBs after transfection with inhibitor NC and miR-98 inhibitor. *P < 0.05 and **P < 0.01, compared with inhibitor NC group, the relative expression, cell viability or apoptosis portion of HSFBs in miR-98 inhibitor had significant difference.
In conclusion, our findings revealed that overexpression of miR-98 repressed the proliferation of HSFBs by targeting Col1A1. Enforced overexpression of miR-98 led to marked reduction of Col1A1 production, which indicated miR-98 was a new method to prevent scar. All those results indicate that miRNAs have a key role in skin fibroblasts.

**Abbreviations**
HS: hypertrophic scarring; HSFBs: hypertrophic scar fibroblasts; bFGF: basic fibroblast growth factor; miRNAs: microRNAs; Trx1: thioredoxin; NSFBs: normal skin fibroblasts; FCS: fetal calf serum; RIPA: radio immunoprecipitation assay; BSA: bovine serum albumin; FCM: flow cytometry; ECM: extracellular matrix; HCPT: hydroxycamptothecin.

**Authors’ contributions**
SB and LLC performed the study and they were major contributors in writing the manuscript. XY and CC analyzed and interpreted the patient data. SB and
SRL contributed to literature research. CC and SRL reviewed the manuscript. All authors read and approved the final manuscript.

Acknowledgements
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
All data generated or analysed during this study are included in this published article.

Ethics approval and consent to participate
The experiments were approved by ethics committee of Central South University (the certificate number was CSU011-094). The written informed consents had been signed by all patients in advance.

Funding
This article was supported by the grants from the National Natural Science Foundation of China (The research on Rac 1-regulated ESCs functions during wound healing, Grant No.: cscx2013-jcyjA10138).

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 17 August 2016   Accepted: 9 June 2017

Published online: 19 June 2017

References
1. Aarabi S, Longaker MT, Gurtner GC. Hypertrophic scar formation following burns and trauma: new approaches to treatment. PLoS Med. 2007;4(9):e234.
2. Zhu Z, Ding J, Shankowsky HA, Tredget EE. The molecular mechanism of hypertrophic scar. J Cell Commun Signal. 2013;7(4):239–52.
3. Akimoto S, Ishikawa O, Iijima C, Miyachi Y. Expression of basic fibroblast growth factor and its receptor by fibroblast, macrophages and mast cells in hypertrophic scar. Eur J Dermatol. 1999;9(5):537–62.
4. Virag JA, Rolle ML, Reece J, Hardouin S, Feigl EO, Murry CE. Fibroblast growth factor-2 regulates myocardial infarct repair: effects on cell proliferation, scar contraction, and ventricular function. J Mol Cell Cardiol. 2007;171(15):1431–40.
5. Ghahary A, Ghaffari A. Role of keratinocyte-fibroblast cross-talk in development of hypertrophic scar. Wound Repair Regen. 2007;15(1):46–53.
6. Xie JL, Jian HN, Qi SH, Chen HD, Xu YB, Li TZ, Li XS, Liang HZ, Xin BR, et al. Basic fibroblast growth factor (bFGF) alleviates the scar of the rabbit ear model in wound healing. Wound Repair Regen. 2008;16(4):576–81.
7. Xiao K, Luo X, Wang X, Gao Z. MicroRNA-185 regulates transforming growth factor-β1 and collagen-I in hypertrophic scar fibroblasts. Mol Med Rep. 2017;15(4):1489–96.
8. Guofang Z, Zhong F, Jin L, Shaojun L, Zhang P. Resveratrol-mediated reduction of collagen by inhibiting proliferation and producing apoptosis in human hypertrophic scar fibroblasts. Biosci Biotechnol Biochem. 2013;77(12):2383–96.
9. Li C, Zhu H-Y, Bai W-D, Su L-L, Liu J-Q, Cai W-X, Zhao B, Gao J-X, Han S-C, Li J. miR-10a and miR-181c regulate collagen type I expression in human hypertrophic scar fibroblasts: Bioinfo Biotechnol Biochem. 2013;77(12):2383–96.
10. Li C, Zhu H-Y, Bai W-D, Su L-L, Liu J-Q, Cai W-X, Zhao B, Gao J-X, Han S-C, Li J. miR-10a and miR-181c regulate collagen type I expression in hyperrophic scars by targeting PAI-1 and uPA. FEBS Lett. 2015;589(3):380–9.
11. Xie JL, Qi S, Yuan J, Xu Y, Li T, Li H, Liu X, Shu B, Liang H. Effects of antisense oligodeoxynucleotide to type I collagen gene on hypertrophic scars in the transplanted nude mouse model. J Cutan Pathol. 2009;36(11):1146–50.
12. Gras C, Ratuszny D, Hadamitzky C, Zhang H, Blaszyck R, Figueiredo C. miR-145 contributes to hypertrophic scarring of the skin by inducing myofibroblast activity. Mol Med. 2015;21(1):296.
13. Barzel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.
14. Eulalio A, Huentzinger E, Zauralde E. Getting to the root of miRNA-mediated gene silencing. Cell. 2008;132(1):9–14.
15. Sonkoly E, Wei T, Janson PC, Säfl A, Lundeberg L, Tengvall-Linder M, Norstedt G, Alenius H, Homey B, Scheinuia A. MicroRNAs: novel regulators involved in the pathogenesis of psoriasis? PLoS ONE. 2007;2(7):e610.
16. Mueller DW, Rehl M, Bosserhoff AK. miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma. J Invest Dermatol. 2009;129(7):1740–51.
17. Siragam V, Rutnam ZJ, Yang W, Fang L, Luo Y, Xing Y, Li M, Deng Z, Qian J, Peng C. MicroRNA miR-98 inhibits tumor angiogenesis and invasion by targeting activin receptor-like kinase-4 and matrix metalloproteinase-11. Oncotarget. 2012;3(11):1570–85.
18. Deng Z-Q, Yin J-Y, Tang Q, Liu F-Q, Qian J, Lin J, Shao R, Zhang M, He L. Over-expression of miR-98 in FFPE tissues might serve as a valuable source for biomarker discovery in breast cancer patients. Int J Clin Exp Pathol. 2014;7(3):1166–71.
19. Hu Y-K, Wang X, Li L, Du Y-H, Ye H-T, Li C-Y. MicroRNA-98 induces an Alzheimer’s disease-like disturbance by targeting insulin-like growth factor 1. Neurosci Bull. 2013;29(6):745–51.
20. Wang J, Yang X. The function of miRNA in cardiac hypertrophy. Cell Mol Life Sci. 2012;69(21):3561–70.
21. Zhao G, Cai C, Yang T, Qiu X, Liao B, Li W, Ji Z, Zhao J, Zhao H, Guo M. MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. PLoS ONE. 2013;8(11):e73906.
22. Aarabi S, Bhatt KA, Shi Y, Paterno, J, Chang EL, Loh SA, Holmes JW, Longaker MT, Yee H, Gurtner GC. Mechanical load initiates hypertrophic scarring through decreased cellular apoptosis. FASEB J. 2007;21(12):3250–61.
23. Atiyeh BS. Nonsurgical management of hypertrophic scars: evidence-based therapies, standard practices, and emerging methods. Aesthetic Plastic Surg. 2007;31(5):468–92.
24. Wang J, Dodd C, Shankowsky HA, Scott PG, Tredget EE. Deep dermal fibroblasts contribute to hypertrophic scarring. Lab Invest. 2008;88(12):1278–90.
25. Ong CT, Khoo YT, Tan EK, Mukhopadhyay A, Do D, Han HC, Lim IL, Phan TT. Epithelial–mesenchymal interactions in keloid pathogenesis modulate vascular endothelial growth factor expression and secretion. J Pathol. 2007;211(1):95–108.
26. Dahlia N, Sherman-Baust CA, Wang T-L, Davidson B, Shih I-M, Zhang Y, Wood W III, Becker KG, Morin PJ. MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS ONE. 2008;3(6):e2436.
27. Cheng J, Wang Y, Wang D, Wu Y. Identification of collagen I as a post-transcriptional target of miR-29b in skin fibroblasts: therapeutic implication for scar reduction. Am J Med Sci. 2013;346(2):98–103.
28. Syed F, Ahmad E, Iqbal S, Singh S, McGrouther D, Bayat A. Fibroblasts from the growing margin of keloid scars produce higher levels of collagen I and III compared with intralesional and extralesional sites: clinical implications for lesional site-directed therapy. Br J Dermatol. 2011;164(4):83–96.
29. Dong H, Kuan-Hong S, Hong-qang W. Pressure therapy upregulates matrix metalloproteinase expression and downregulates collagen expression in hypertrophic scar tissue. Chin Med J. 2013;126(7):3231–2.
30. Zgeibe C, Xu J, Liechty KW. Targeting inflammatory cytokines and extracellular matrix composition to promote wound regeneration. Adv Wound Care. 2014;3(4):344–55.
31. Deng C, Zheng J, Wan W, Zhang S, Ding Z, Mao G, Yang S. Suppression of cell proliferation and collagen production in cultured human hypertrophic scar fibroblasts by Sp1 decoy oligodeoxynucleotide. Mol Med Rep. 2013;7(3):785–90.
32. Linjawi SA, Tork SE. SHABIAH RM: genetic association of the COL1A1 gene promoter? 1997 G/T (rs1107946) and Sp1 promoter polymorphisms and keloid scars in a Jeddah population. Turk J Med Sci. 2016;46(2):414–23.
33. Scharstuhl A, Mutsaers H, Pennings S, Szarek W, Russel F, Wagener F. Curcumin-induced fibroblast apoptosis and in vitro wound contraction are regulated by antioxidants and heme oxygenase: implications for scar formation. J Cell Mol Med. 2009;13(4):712–25.

34. Sun Y, Wang L, Sun S, Liu B, Wu N, Cao X. The effect of 10-hydroxycamptothecine in preventing fibroblast proliferation and epidural scar adhesion after laminectomy in rats. Eur J Pharmacol. 2008;593(1):44–8.

35. Lorenz HP, Lin RY, Longaker MT, Whitby DJ, Adzick NS. The fetal fibroblast: the effector cell of scarless fetal skin repair. Plast Reconstr Surg. 1995;96(6):1251–9.